Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant <i>KIT</i> D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia.

Kampa-Schittenhelm, Kerstin Maria; Frey, Julia; Haeusser, Lara A; Illing, Barbara; Pavlovsky, Ashly A; Blumenstock, Gunnar; Schittenhelm, Marcus Matthias

Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant KIT D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia.

Kampa-Schittenhelm, Kerstin Maria; Frey, Julia; Haeusser, Lara A; Illing, Barbara; Pavlovsky, Ashly A; Blumenstock, Gunnar; Schittenhelm, Marcus Matthias.

Afiliação

Kampa-Schittenhelm KM; University Hospital Tübingen, Department of Oncology, Hematology, Rheumatology, Clinical Immunology and Pulmology, Tübingen, Germany.
Frey J; University Hospital Tübingen, Department of Oncology, Hematology, Rheumatology, Clinical Immunology and Pulmology, Tübingen, Germany.
Haeusser LA; University Hospital Tübingen, Department of Oncology, Hematology, Rheumatology, Clinical Immunology and Pulmology, Tübingen, Germany.
Illing B; University Hospital Tübingen, Department of Oncology, Hematology, Rheumatology, Clinical Immunology and Pulmology, Tübingen, Germany.
Pavlovsky AA; Arog Pharmaceuticals, Inc., Dallas, Texas, USA.
Blumenstock G; Institute of Clinical Epidemiology and Applied Biometry, Eberhard Karls University Tübingen, Tübingen, Germany.
Schittenhelm MM; University Hospital Tübingen, Department of Oncology, Hematology, Rheumatology, Clinical Immunology and Pulmology, Tübingen, Germany.

Oncotarget ; 8(47): 82897-82909, 2017 Oct 10.

Article em En | MEDLINE | ID: mdl-29137311